Table 1.
Nanoformulations of resveratrol for cancer therapy.
| Formulation/details | Tested system | Experimental results | References |
|---|---|---|---|
| Nanoparticles mPEG–PCL based nanoparticles |
C6 glioma cells | • Increased cell death, cytotoxicity and intracellular ROS levels production compared to free resveratrol | Shao et al. (2009) |
| Resveratrol-loaded poly(ε-caprolactone) nanocapsules | Murine melanoma cell and mice model | • Inhibited cell growth and induced cell death • Reduced tumor volume and increased necrotic area and inflammatory infiltrate |
Carletto et al. (2016) |
| Resveratrol-capped gold nanoparticles(Size: 22.28 ± 2.98 nm in diameter) | Human breast cancer cells | • Inhibited breast cancer cell progression by influencing the matrix metalloproteinase, cyclooxygenase-2, nuclear transcription factor-κB, activator protein-1, phosphoinositide 3-kinase/Akt (PI3K/Akt) and extracellular signal-regulated kinase | Park et al. (2016) |
| Resveratrol-doxorubicin-loaded gold nanoparticles (resveratrol_GnanoparticleS) (Average size and zeta potential: 35 nm and −21.2 mV) | Glioma carcinoma cell line | • Enhanced anticancer activity • IC50 value for doxorubicin loaded resveratrol-Gnanoparticles and free doxorubicin are 4 μg/mL and 6 μg/mL, respectively |
Mohanty et al. (2014) |
| Zein/pectin core-shell nanoparticles (size ≈235 nm in diameter and contain resveratrol content of 10.2%, w/w) | Human hepatocarcinoma Bel-7402 cells | • Exhibited higher antiproliferative activity (IC50 = 17.6 μg/mL, 77.2 μM) as compared to free resveratrol (IC50 = 25.6 μg/mL, 112.0 μM) | Huang et al. (2017) |
| Radiolabeled resveratrol-loaded gold nanoparticles | HT29 colon cancer cells and hepatocellular carcinoma bearing animal model | • Cancer cell internalization for 99mTc-Res-Au nanoparticle was significantly higher than that of 99mTc-Au nanoparticle and 99mTc-resveratrol. • Gradual rise in target to nontarget uptake over time was observed following i.v. administration of 99mTc-Res-Au nanoparticle to colon tumor bearing rats |
Kamal et al. (2018) |
| Liposomes Ultra-deformable liposomes (Resveratrol and 5-fluorouracil co-loaded) |
SK-MEL-28 cells and Colo-38 cells | • High ability to block cell proliferation in G1/S, modifying the action of 5-fluorouracil and increasing the activity of resveratrol | Cosco et al. (2015) |
| Chitosan (CTS) modified liposomes, and coated by gold nanoshells (GNS@CTS@Res-lips) | HeLa cells | • Efficient on-demand pH/photothermal-sensitive drug release and improved drug cellular uptake and cytotoxicity | Wang et al. (2017) |
| Liposomes | PTEN-CaP8 cells and PTEN knockout mice | • Inhibited cell growth and induced apoptosis in PTEN-CaP8 cells • Downregulated p-Akt, cyclin D1, mTOR, and AR • Decreased prostatic adenocarcinoma with significant raise in curcumin concentration when co-administered with resveratrol |
Narayanan et al. (2009) |
| Cyclodextrin cyclodextrin-based nanosponges (size between 400 to 500 nm) |
HCPC-I cells | • Improved in vitro release and stability as compared to plain drug • Higher toxicity effects compared to free resveratrol |
Ansari et al. (2011) |
| Nanoemulsion (lipid based nanoemulsifying resveratrol) | MCF-7 breast cancer cells | • Enhanced cytotoxicity | Pund et al. (2014) |
| Other approaches Lactobionic/folate dual-targeted amphiphilic maltodextrin-based micelles(resveratrol and sulfasalazine) |
HepG-2 liver cancer cell | • Dual-targeted micelles enhanced cytotoxicity via binding to overexpressed folate and asialoglycoprotein receptors and showed improved cellular uptake • In vivo: Reduced liver/body weight ratio via stimulation of apoptotic enzyme, 3 and suppression of the VEGF (tumor angiogenic marker) |
Anwar et al. (2018) |